drugset / Trial / NCT02279615
Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.
RandomizedSingle-groupDouble-blindTreatment
Summary
The purpose of this study is to investigate the safety and efficacy of combination therapy involving β3-adrenoceptor agonist, mirabegron, and α-blockers for the treatment of OAB symptoms in male patients with BPH.
Timeline
- Start
- 2021-12
- Primary completion
- 2022-12
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mirabegron | Other / unclassified | 50 mg | — |
| Comparator | Tamsulosin | Other / unclassified | 0.4 mg | — |